Cohort 2

DRUG8 trials

Conditions

Anaplastic AstrocytomaAsthmaAstrocytic TumorsBrain TumorChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia ThalassemiaCongenital HyperinsulinismGlioblastoma MultiformeHealthy

Phase 1

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

CompletedNCT00439179

Brown UniversityMetastatic Pancreatic Cancer

Start: 2006-07-31End: 2007-12-31Updated: 2020-02-17

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

CompletedNCT01400555

Cougar Biotechnology, Inc.Prostate Cancer, Prostate Neoplasms

Start: 2011-09-01End: 2017-02-28Updated: 2018-03-21

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

CompletedNCT01516047

Janssen Research & Development, LLCHepatic Impairment

Start: 2012-01-31End: 2012-09-30Updated: 2014-06-25

Phase I Study of Safety and Immunogenicity of ADU-623

CompletedNCT01967758

Providence Health & ServicesAnaplastic Astrocytoma, Astrocytic Tumors, Brain Tumor +1

Start: 2014-01-08End: 2018-08-15Updated: 2018-08-17

Phase 2

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

CompletedNCT02604485

XOMA (US) LLCCongenital Hyperinsulinism

Start: 2015-10-31End: 2017-01-31Updated: 2017-02-06

A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) ß-Thalassemia Subjects with Chronic Anemia

Active, not recruitingLBCTR2019020179

Protagonist Therapeutics IncChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia Thalassemia

Start: 2019-03-11Target: 84Updated: 2026-02-02

Phase 4

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

CompletedNCT00777764

Genentech, Inc.Asthma, Healthy

Start: 2008-08-31End: 2009-04-30Updated: 2017-06-14

Unknown Phase

Identification and Description of Patients With High-risk Non Metastatic RCC

RecruitingNCT07753343

University Hospital, BordeauxRenal Cell Carcinoma

Start: 2026-04-17End: 2028-04-17Target: 6109Updated: 2026-08-07

Journal of Clinical Oncology2015-05-201 citations

Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-202 citations

Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-02-011 citations